Auerbach Hematology and Oncology Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Baltimore MD United States

Organization Overview

First Clinical Trial
2011
NCT01374919
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Auerbach Hematology and Oncology | Auerbach Hematology and Oncology Associates, PC | Auerbach Hematology Oncology | Auerbach Hematology Oncology Associates P C

Active Ingredients

Drugs in Phase 4 Trials (2)

ferrous sulfate (3 trials)

ferumoxytol (feraheme) (4 trials)

Drugs in Phase 3 Trials (1)

vitamin c (1 trial)

Drugs in Phase 2 Trials (1)

low molecular weight iron dextran (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 4)

Anemia, Iron-Deficiency (Phase 4)

Deficiency Diseases (Phase 3)

Psychomotor Agitation (Phase 2)

Restless Legs Syndrome (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 4